Brief: Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101
01/06/2026 12:21
BRIEF-Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 June 1 (Reuters) - Jade Biosciences Inc JBIO.O:
JADE BIOSCIENCES - JADE101 SUSTAINS ~70% IGA REDUCTION AT 12 WEEKS AFTER SINGLE DOSE
JADE BIOSCIENCES - JADE101 WELL-TOLERATED ACROSS ALL EVALUATED DOSES
JADE BIOSCIENCES - JADE101 PROJECTS >70% IGA REDUCTION WITH EVERY-12-WEEK MAINTENANCE DOSING
JADE BIOSCIENCES - PHASE 2 TRIAL IN IGA NEPHROPATHY UNDERWAY, INTERIM DATA EXPECTED IN 2027
JADE BIOSCIENCES - PHASE 3 REGISTRATIONAL TRIAL EXPECTED TO INITIATE IN FIRST HALF OF 2027
Source text: ID:nGNXbRgxKF
Further company coverage: JBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million